[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,098,020
  • Shares Outstanding, K 158,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -512,540 K
  • EBIT $ -547 M
  • EBITDA $ -546 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.45

Options Overview Details

View History
  • Implied Volatility 69.74% (+8.10%)
  • Historical Volatility 50.81%
  • IV Percentile 20%
  • IV Rank 15.14%
  • IV High 155.38% on 11/13/25
  • IV Low 54.46% on 08/18/25
  • Expected Move (DTE 11) 2.05 (10.49%)
  • Put/Call Vol Ratio 2.10
  • Today's Volume 737
  • Volume Avg (30-Day) 1,177
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 13,105
  • Open Int (30-Day) 10,795
  • Expected Range 17.47 to 21.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.73
  • Number of Estimates 10
  • High Estimate $-0.67
  • Low Estimate $-0.89
  • Prior Year $-0.72
  • Growth Rate Est. (year over year) -1.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.71 +10.22%
on 05/19/26
21.18 -7.84%
on 05/29/26
+0.60 (+3.17%)
since 05/05/26
3-Month
17.71 +10.22%
on 05/19/26
23.46 -16.79%
on 03/25/26
-0.18 (-0.91%)
since 03/05/26
52-Week
12.58 +55.17%
on 09/22/25
23.77 -17.88%
on 02/03/26
+5.30 (+37.27%)
since 06/05/25

Most Recent Stories

More News
Stocks Settle Higher on Iran Peace Hopes and Tech Strength

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. June E-mini S&P...

AMAT : 453.01 (-9.71%)
INTU : 296.76 (-1.73%)
ADI : 401.39 (-6.38%)
DDOG : 234.11 (-3.90%)
MRK : 120.79 (+0.44%)
TXN : 285.06 (-6.65%)
$IUXX : 28,957.60 (-4.77%)
COIN : 152.40 (-7.15%)
ASML : 1,641.74 (-6.59%)
ZNU26 : 109-025s (-0.47%)
ESM26 : 7,400.50s (-2.64%)
QCOM : 215.94 (-10.98%)
Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.73%. June E-mini S&P futures (ESM26...

AMAT : 453.01 (-9.71%)
INTU : 296.76 (-1.73%)
ADI : 401.39 (-6.38%)
DDOG : 234.11 (-3.90%)
MRK : 120.79 (+0.44%)
TXN : 285.06 (-6.65%)
$IUXX : 28,957.60 (-4.77%)
ASML : 1,641.74 (-6.59%)
ZNU26 : 109-025s (-0.47%)
ESM26 : 7,400.50s (-2.64%)
QCOM : 215.94 (-10.98%)
IBM : 284.84 (-5.61%)
Stocks Supported by US-Iran Peace Deal Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.54%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.53%. June E-mini S&P futures (ESM26...

AMAT : 453.01 (-9.71%)
INTU : 296.76 (-1.73%)
ADI : 401.39 (-6.38%)
DDOG : 234.11 (-3.90%)
MRK : 120.79 (+0.44%)
TXN : 285.06 (-6.65%)
$IUXX : 28,957.60 (-4.77%)
ASML : 1,641.74 (-6.59%)
ZNU26 : 109-025s (-0.47%)
MSFT : 416.67 (-2.66%)
ESM26 : 7,400.50s (-2.64%)
QCOM : 215.94 (-10.98%)
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints  Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue...

DNLI : 19.52 (-3.08%)
BIIB : 195.34 (-0.57%)
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and...

DNLI : 19.52 (-3.08%)
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

FDA approved AVLAYAH™ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrier AVLAYAH launched in U.S....

DNLI : 19.52 (-3.08%)
Denali's First Commercial Quarter Will Show Whether Hunter Syndrome Launch Mechanics Actually Work

Barchart Research What to Expect from DNLI Earnings DNLI Generated May 4, 2026 Current Price $18.67 EPS Estimate $$-0.73 Consensus Rating Strong Buy Average Move 5.31% Denali's First Commercial Quarter...

DNLI : 19.52 (-3.08%)
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technology Results from ongoing Phase 1/2 study in patients with...

DNLI : 19.52 (-3.08%)
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage...

DNLI : 19.52 (-3.08%)
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease First FDA-approved medicine in emerging new class of biotherapeutics that leverage...

DNLI : 19.52 (-3.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 20.59
2nd Resistance Point 20.27
1st Resistance Point 19.89
Last Price 19.52
1st Support Level 19.19
2nd Support Level 18.87
3rd Support Level 18.49

See More

52-Week High 23.77
Last Price 19.52
Fibonacci 61.8% 19.50
Fibonacci 50% 18.17
Fibonacci 38.2% 16.85
52-Week Low 12.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.